What is the recommended protocol for managing a needle‑stick injury, including immediate wound care, reporting, exposure assessment, testing, HIV post‑exposure prophylaxis, hepatitis B vaccination and immune globulin, hepatitis C follow‑up, and subsequent follow‑up testing?

Needle Stick Injury Protocol

Immediately wash the wound with soap and water (or flush mucous membranes with water), then rapidly assess the source patient's bloodborne pathogen status and initiate appropriate post-exposure prophylaxis within 2 hours for HIV and provide hepatitis B immunization/immunoglobulin based on the exposed person's vaccination status. 1

Immediate Wound Care (First Minutes)

• Wash wounds and skin with soap and water – do not squeeze or scrub aggressively
• Flush mucous membranes with water if splash exposure occurred
• Encourage bleeding from the puncture site briefly
• Do NOT apply caustic agents like bleach or iodine to the wound 1, 2

Risk Assessment (Within First Hour)

Evaluate the Exposure Type

Assess risk based on:

• Type of fluid: blood, visibly bloody fluid, other potentially infectious fluid/tissue, or concentrated virus
• Type of exposure: percutaneous injury (hollow-bore needle carries highest risk), mucous membrane exposure, nonintact skin exposure, or bite with blood exposure 1

Evaluate the Source Patient

• Test known sources immediately for HBsAg, anti-HCV, and HIV antibody (consider rapid HIV testing for faster results)
• For unknown sources, assess epidemiologic risk of HBV, HCV, or HIV infection
• Do NOT test discarded needles or syringes for virus contamination – this is unreliable 1

Evaluate the Exposed Person

• Determine hepatitis B vaccination history and documented vaccine response (anti-HBs status)
• Obtain baseline serologic testing for HBV, HCV, and HIV 1

Post-Exposure Prophylaxis (Within 2 Hours Ideally, Up to 72 Hours)

HIV Post-Exposure Prophylaxis

• Initiate within 2 hours when possible (85.1% compliance in one study), though can be started up to 72 hours post-exposure 3
• Use a basic regimen: Zidovudine (ZDV) 600 mg/day in 2-3 divided doses + Lamivudine (3TC) 150 mg twice daily (available as single tablet Combivir twice daily) 1
• Alternative regimens include 3TC + Stavudine (d4T) or Didanosine (ddI) + d4T for patients with contraindications or if source virus resistance is suspected 1
• Continue for 28 days (though guidelines reference 6 weeks in some contexts)
• Monitor for drug toxicity with baseline labs and clinical evaluation every 2 weeks 1

Common Pitfall: Delaying HIV PEP beyond 2 hours significantly reduces efficacy. The median door-to-PEP time should be under 90 minutes 4.

Hepatitis B Post-Exposure Management

Management depends on the exposed person's vaccination and immunity status:

• If exposed person is vaccinated and known responder (anti-HBs ≥10 mIU/mL): No treatment needed
• If exposed person is unvaccinated: Give hepatitis B immunoglobulin (HBIG) immediately AND initiate hepatitis B vaccine series
• If exposed person has incomplete vaccination or unknown response: Give HBIG and complete/restart vaccine series
• If exposed person is known non-responder: Give HBIG × 2 doses (immediately and at 1 month) 1

Test for anti-HBs response 1-2 months after completing vaccine series (note: cannot assess vaccine response if HBIG given within previous 3-4 months) 1.

Hepatitis C Post-Exposure Management

• No post-exposure prophylaxis is recommended for HCV 1
• Proceed directly to monitoring (see below)

Reporting and Documentation

• Report the incident immediately to occupational health or designated personnel available 24/7
• Document exposure details: date/time, circumstances, type of device, depth of injury, source patient information
• Complete institutional accident/incident report
• Notify workers' compensation/accident insurance as appropriate 1, 5

Follow-Up Testing Schedule

Hepatitis B

• Test for anti-HBs 1-2 months after last vaccine dose (if vaccine given)
• Remember: anti-HBs response cannot be accurately assessed if HBIG received in previous 3-4 months 1

Hepatitis C

• Baseline: anti-HCV and ALT at time of exposure
• 4-6 months: Repeat anti-HCV and ALT
• Optional early detection: HCV RNA at 4-6 weeks if earlier diagnosis desired
• Confirm repeatedly reactive anti-HCV enzyme immunoassays with supplemental testing 1

HIV

• Baseline: HIV antibody test at time of exposure
• 6 weeks: HIV antibody
• 3 months: HIV antibody
• 6 months: HIV antibody (minimum follow-up duration)
• Test immediately if acute retroviral syndrome symptoms develop (fever, rash, lymphadenopathy, pharyngitis) 1

Critical Point: Advise exposed persons to use precautions to prevent secondary transmission during the 6-month follow-up period (barrier protection during sexual activity, avoid blood/organ donation, avoid breastfeeding if applicable) 1.

Counseling and Psychological Support

• Provide emotional support counseling – 87% of healthcare workers report psychological distress following needle stick injury, with 12.2% reporting severe concern 3, 6
• Offer medication adherence counseling for those on HIV PEP to ensure completion
• Advise to seek immediate medical evaluation for any acute illness during follow-up period 1

Key Prevention Points for Future

• Never recap needles – this accounts for a significant proportion of injuries 2, 6
• Use safety-engineered devices with retractable needles when available
• Dispose of sharps in puncture-resistant containers when three-quarters full
• Ensure hepatitis B vaccination for all healthcare workers (68.7% coverage in one study is insufficient) 6
• Maintain universal precautions during all patient procedures 1

Important Caveat: These guidelines are based on 2001 U.S. Public Health Service recommendations [1-1]. While the fundamental principles remain valid and are supported by more recent observational data showing zero seroconversion with proper management 3, 2, clinicians should verify current institutional protocols and consider consulting updated CDC or local guidelines for the most recent antiretroviral regimens for HIV PEP, as drug recommendations have evolved.